EUVIMEDEUVIMED entdecken
Übersichtsarbeit

First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis -specific Th1-cell like responses

Tom H M Ottenhoff, T Mark Doherty, Jaap T van Dissel, Peter Bang, Karen Lingnau, Ingrid Kromann, Peter Andersen

Human Vaccines · 2010-12 · 6 (12) · 1007-1015

DOI: 10.4161/hv.6.12.13143 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Vaccines, online erschienen am 27.10.2014. Verfasst von Tom H M Ottenhoff und 6 weiteren Autor:innen. Beteiligte Einrichtung: Leiden University Medical Center, Dept. of Infectious Diseases, Leiden, The Netherlands. t.h.m.ottenhoff@lumc.nl. Die Arbeit wurde bisher 56-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) remains a major killer worldwide. The only available TB-vaccine, the nearly century-old Mycobacterium bovis BCG, has had only a limited effect on TB incidence. Therefore, developing new TB vaccines is a key priority, and the first new generation TB vaccines are now being tested in clinical trials. Here we describe the development and first testing in humans of a novel, wholly synthetic TB subunit vaccine. This vaccine has proven safe and highly immunogenic in all species in which it was tested, including mice, guinea pigs, non-human primates and humans. Most encouragingly, following vaccination in humans, strong IFN-γ responses persisted through at least 2½ years of follow-up, indicating induction of a substantial memory response by this new TB vaccine. These findings encourage further preclinical and clinical studies with TB subunit vaccines and cellular immunity-stimulating new adjuvants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsGuinea PigsHumansInterferon-gammaMiceMycobacterium tuberculosisTh1 CellsTime FactorsTuberculosis VaccinesVaccines, SubunitVaccines, Synthetic

Substanzen

Tuberculosis VaccinesVaccines, SubunitVaccines, SyntheticInterferon-gamma

Autor:innen und Institutionen

  • Leiden University Medical Center, Dept. of Infectious Diseases, Leiden, The Netherlands. t.h.m.ottenhoff@lumc.nl

Zitieren

APA

Ottenhoff, T. H., Doherty, T. M., van Dissel, J. T., Bang, P., Lingnau, K., Kromann, I., & Andersen, P. (2010). First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis -specific Th1-cell like responses. Human Vaccines, 6(12), 1007-1015. https://doi.org/10.4161/hv.6.12.13143

Vancouver

Ottenhoff TH, Doherty TM, van Dissel JT, Bang P, Lingnau K, Kromann I, et al. First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis -specific Th1-cell like responses. Human Vaccines. 2010;6(12):1007-1015. doi:10.4161/hv.6.12.13143

BibTeX
@article{Ottenhoff2010,
  author = {Ottenhoff, Tom H M and Doherty, T Mark and van Dissel, Jaap T and Bang, Peter and Lingnau, Karen and Kromann, Ingrid and Andersen, Peter},
  title = {First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis -specific Th1-cell like responses},
  journal = {Human Vaccines},
  year = {2010},
  volume = {6},
  number = {12},
  pages = {1007--1015},
  doi = {10.4161/hv.6.12.13143}
}
Kostenlos starten →